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Background
Recommended by Resolution of Immunotherapy, issued
by EAACI, Specific immunotherapy (SIT) was established
as a mainstream method of treating allergic diseases. SIT
produces long term challenges. SIT team should be aware
that at first injection of allergen, the immunotherapy may
cause a long lasting reaction. Anaphylaxis during SIT is
very rare, but it is possible. We’ve experienced anaphylaxis
after four year of SIT, against ragweed allergen.
Methods
A fifty four year old female went into anaphylactic shock
after four years of SIT against ragweed allergen. Before
the start of SIT, complete diagnostic procedures had
been performed. Intradermal skin tests were performed
for standard pallet of contact, inhalation, and nutritional
allergens. The female patient tested positive for Ragweed
(high positive), fungi (aspergillum fumigates, altenaria),
and milk. Total IgE was measured using Enzyme Linked
Immunoassay (ELISA).
Result
After injection of the SIT maintenance dose (0.2 ml of sec-
ond concentration of allergen, (product of authorized
Immunologic Laboratory Production) against ragweed,
anaphylaxis developed within five minutes. The first mani-
festation was itchy palms and itching of eyes, followed by
a rash. A dose of 0.0005 gram epinephrine was adminis-
tered subcutaneously immediately. After the epinephrine
injection, an IV rout was established with 0.9 % saline
infusion, 0.2 gram of hydrocortisone, and 0.020 gram of
chloropiramin was administered intramuscularly. No
bronchoobstruction developed. Patient displayed anxiety.
After an hour of treatment, the symptoms of anaphylaxis
subsided.
Conclusion
Anaphylaxis can develop as a complication of SIT with
any possible manifestation. Treatment of anaphylaxis
should start immediately after initial symptoms. The use
of epinephrine is recommended.
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